Astragaloside IV Supplementation Promotes A Neuroprotective Effect in Experimental Models of Neurological Disorders: A Systematic Review.
Astragaloside IV Supplementation Promotes A Neuroprotective Effect in Experimental Models of Neurological Disorders: A Systematic Review.
复制标题
DOI：
10.2174/1570159x16666180911123341
复制
发表时间：
2019
影响因子：
5.3
通讯作者：
Guzen FP
中科院分区：
文献类型：
--
作者：
Costa IM;Lima FOV;Fernandes LCB;Norrara B;Neta FI;Alves RD;Cavalcanti JRLP;Lucena EES;Cavalcante JS;Rego ACM;Filho IA;Queiroz DB;Freire MAM;Guzen FP
由于人口的逐渐老龄化及其所代表的危险行为，神经系统疾病构成了一个日益受到全世界关注的问题。草药在治疗这些疾病方面具有科学意义。其中一种物质黄芪甲苷（AS-IV）是黄芪（Astragalus membranaceus）根中的主要活性化合物。一种具有神经保护作用的中草药。在本研究中，我们进行了一项系统综述，试图理解AS-IV在神经系统疾病实验模型中所表现出的神经保护作用。本研究是一项系统综述，通过Proquest和Periodicos Capes数据库对美国国家医学图书馆（Pub-Med）、Science Direct、Cochrane图书馆、Science electronic Library Online （SciELO）、Scopus、Web of Science、Medline进行2007 - 2017年的电子检索，使用“黄芪甲苷IV”和“神经退行性疾病”；以“黄芪甲苷”和“神经系统疾病”作为参考术语。共有16篇文章被确定，其中AS-IV在帕金森氏病、阿尔茨海默病、脑缺血和自身免疫性脑脊髓炎的实验模型中通过改善运动缺陷和/或神经化学活性，特别是抗氧化系统，减少炎症和氧化应激的功效。本研究结果表明，as - iv可以改善行为和神经化学缺陷，主要是由于其抗氧化、抗凋亡和抗炎特性，成为治疗神经系统疾病的一种替代治疗方法。
Neurological disorders constitute a growing worldwide concern due to the progressive aging of the population and the risky behavior they represent. Herbal medicines have scientific relevance in the treatment of these pathol-ogies. One of these substances, Astragaloside IV (AS-IV), is the main active compound present in the root of Astragalus membranaceus (Fisch.) Bge, a Chinese medicinal herb with neuroprotective properties. In the present study we performed a systematic review that sought to comprehend the neuroprotective effect pre-sented by AS-IV in experimental models of neurological disorders. This study is a systematic review, where an electronic search in United States National Library of Medicine (Pub-Med), Science Direct, Cochrane Library, Scientific Electronic Library Online (SciELO), Scopus, Web of Science, Medline via Proquest and Periodicos Capes databases covering the years between 2007 and 2017, using “Astragaloside IV” and “Neurodegenerative diseases”; “Astragaloside IV” and “ Neurological disorders” as reference terms was made. A total of 16 articles were identified, in which the efficacy of AS-IV was described in experimental models of Par-kinson’s disease, Alzheimer’s disease, cerebral ischemia and autoimmune encephalomyelitis, by improving motor deficits and/or neurochemical activity, especially antioxidant systems, reducing inflammation and oxidative stress. The findings of the present study indicate that the administration of AS-IV can improve behavioral and neuro-chemical deficits largely due to its antioxidant, antiapoptotic and anti-inflammatory properties, emerging as an alternative therapeutic approach for the treatment of neurological disorders.